Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

Summary Background In men with localised prostate cancer, conformal radiotherapy (CFRT) could deliver higher doses of radiation than does standard-dose conventional radical external-beam radiotherapy, and could improve long-term efficacy, potentially at the cost of increased toxicity. We aimed to pr...

Full description

Saved in:
Bibliographic Details
Published in:The lancet oncology 2007-06, Vol.8 (6), p.475-487
Main Authors: Dearnaley, David P, Dr, Sydes, Matthew R, CStat, Graham, John D, FRCR, Aird, Edwin G, PhD, Bottomley, David, FRCR, Cowan, Richard A, FRCR, Huddart, Robert A, FRCR, Jose, Chakiath C, FRACR, Matthews, John HL, FRACR, Millar, Jeremy, FRACR, Moore, A Rollo, MSc, Morgan, Rachel C, MSc, Russell, J Martin, FRCR, Scrase, Christopher D, FRCR, Stephens, Richard J, Syndikus, Isabel, FRCR, Parmar, Mahesh KB, DPhil
Format: Article
Language:English
Subjects:
Aged
Androgen Antagonists - therapeutic use
Androgens
Cancer therapies
Disease control
Disease-Free Survival
Hematology, Oncology and Palliative Medicine
Humans
Male
Metastasis
Middle Aged
Neoadjuvant Therapy
Prostate cancer
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - radiotherapy
Questionnaires
Radiation therapy
Radiotherapy Dosage
Radiotherapy, Conformal
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c445t-681b316880b1b33813e3453a22f8d43b52eb1a4b4d2d157f9a94d997896281673
cites cdi_FETCH-LOGICAL-c445t-681b316880b1b33813e3453a22f8d43b52eb1a4b4d2d157f9a94d997896281673
container_end_page 487
container_issue 6
container_start_page 475
container_title The lancet oncology
container_volume 8
creator Dearnaley, David P, Dr
Sydes, Matthew R, CStat
Graham, John D, FRCR
Aird, Edwin G, PhD
Bottomley, David, FRCR
Cowan, Richard A, FRCR
Huddart, Robert A, FRCR
Jose, Chakiath C, FRACR
Matthews, John HL, FRACR
Millar, Jeremy, FRACR
Moore, A Rollo, MSc
Morgan, Rachel C, MSc
Russell, J Martin, FRCR
Scrase, Christopher D, FRCR
Stephens, Richard J
Syndikus, Isabel, FRCR
Parmar, Mahesh KB, DPhil
description Summary Background In men with localised prostate cancer, conformal radiotherapy (CFRT) could deliver higher doses of radiation than does standard-dose conventional radical external-beam radiotherapy, and could improve long-term efficacy, potentially at the cost of increased toxicity. We aimed to present the first analyses of effectiveness from the MRC RT01 randomised controlled trial. Methods The MRC RT01 trial included 843 men with localised prostate cancer who were randomly assigned to standard-dose CFRT or escalated-dose CFRT, both administered with neoadjuvant androgen suppression. Primary endpoints were biochemical-progression-free survival (bPFS), freedom from local progression, metastases-free survival, overall survival, and late toxicity scores. The toxicity scores were measured with questionnaires for physicians and patients that included the Radiation Therapy Oncology Group (RTOG), the Late Effects on Normal Tissue: Subjective/Objective/Management (LENT/SOM) scales, and the University of California, Los Angeles Prostate Cancer Index (UCLA PCI) scales. Analysis was done by intention to treat. This trial is registered at the Current Controlled Trials website http://www.controlled-trials.com/ISRCTN47772397. Findings Between January, 1998, and December, 2002, 843 men were randomly assigned to escalated-dose CFRT (n=422) or standard-dose CFRT (n=421). In the escalated group, the hazard ratio (HR) for bPFS was 0·67 (95% CI 0·53–0·85, p=0·0007). We noted 71% bPFS (108 cumulative events) and 60% bPFS (149 cumulative events) by 5 years in the escalated and standard groups, respectively. HR for clinical progression-free survival was 0·69 (0·47–1·02; p=0·064); local control was 0·65 (0·36–1·18; p=0·16); freedom from salvage androgen suppression was 0·78 (0·57–1·07; p=0·12); and metastases-free survival was 0·74 (0·47–1·18; p=0·21). HR for late bowel toxicity in the escalated group was 1·47 (1·12–1·92) according to the RTOG (grade ≥2) scale; 1·44 (1·16–1·80) according to the LENT/SOM (grade ≥2) scales; and 1·28 (1·03–1·60) according to the UCLA PCI (score ≥30) scale. 33% of the escalated and 24% of the standard group reported late bowel toxicity within 5 years of starting treatment. HR for late bladder toxicity according to the RTOG (grade ≥2) scale was 1·36 (0·90–2·06), but this finding was not supported by the LENT/SOM (grade ≥2) scales (HR 1·07 [0·90–1·29]), nor the UCLA PCI (score ≥30) scale (HR 1·05 [0·81–1·36]). Interpretation Escalated-dose CFRT with
doi_str_mv 10.1016/S1470-2045(07)70143-2
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_200978787</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1470204507701432</els_id><sourcerecordid>1665199821</sourcerecordid><originalsourceid>FETCH-LOGICAL-c445t-681b316880b1b33813e3453a22f8d43b52eb1a4b4d2d157f9a94d997896281673</originalsourceid><addsrcrecordid>eNqFkctu1TAQhi0EoqXwCCCLFV0EfEvssACho3KRipBKWVtOPBEuSXxqO5XOK_SpmXNyBBIb5IVHo2_-ufyEPOfsNWe8efOdK80qwVT9iulzzbiSlXhATjGtqloZ8_AQr8gJeZLzDWNcc1Y_JidcKyOMYafk_iL3bnQFfOVjBnoHKS-Z5uJm79Ix2cd5iGlyI03Oh1h-QnLbHQ0z3aaIaEHEzT2kt3QIKReaIC9jyXRIcaKI069XG3p1zTgKzD5OIYPfq5YUxxHDkoIbn5JHgxszPDv-Z-THx4vrzefq8tunL5sPl1WvVF2qxvBO8gan7zCQhkuQqpZOiMF4JbtaQMed6pQXntd6aF2rfNtq0zbC8EbLM_Jy1cXhbxfIxd7EJc3Y0grGEMSHUL1CPW6YEwx2m8Lk0s5yZvcG2IMBdn9dy7Q9GGAF1r04ii_dBP5v1fHiCLxfAcAV7wIkm_sAeDwfEvTF-hj-2-LdPwr9GOaANv6CHeQ_y3CbhWWryF6D6YOCkL8BtmuqkQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>200978787</pqid></control><display><type>article</type><title>Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial</title><source>ScienceDirect Freedom Collection</source><creator>Dearnaley, David P, Dr ; Sydes, Matthew R, CStat ; Graham, John D, FRCR ; Aird, Edwin G, PhD ; Bottomley, David, FRCR ; Cowan, Richard A, FRCR ; Huddart, Robert A, FRCR ; Jose, Chakiath C, FRACR ; Matthews, John HL, FRACR ; Millar, Jeremy, FRACR ; Moore, A Rollo, MSc ; Morgan, Rachel C, MSc ; Russell, J Martin, FRCR ; Scrase, Christopher D, FRCR ; Stephens, Richard J ; Syndikus, Isabel, FRCR ; Parmar, Mahesh KB, DPhil</creator><creatorcontrib>Dearnaley, David P, Dr ; Sydes, Matthew R, CStat ; Graham, John D, FRCR ; Aird, Edwin G, PhD ; Bottomley, David, FRCR ; Cowan, Richard A, FRCR ; Huddart, Robert A, FRCR ; Jose, Chakiath C, FRACR ; Matthews, John HL, FRACR ; Millar, Jeremy, FRACR ; Moore, A Rollo, MSc ; Morgan, Rachel C, MSc ; Russell, J Martin, FRCR ; Scrase, Christopher D, FRCR ; Stephens, Richard J ; Syndikus, Isabel, FRCR ; Parmar, Mahesh KB, DPhil ; on behalf of the RT01 collaborators ; RT01 collaborators</creatorcontrib><description>Summary Background In men with localised prostate cancer, conformal radiotherapy (CFRT) could deliver higher doses of radiation than does standard-dose conventional radical external-beam radiotherapy, and could improve long-term efficacy, potentially at the cost of increased toxicity. We aimed to present the first analyses of effectiveness from the MRC RT01 randomised controlled trial. Methods The MRC RT01 trial included 843 men with localised prostate cancer who were randomly assigned to standard-dose CFRT or escalated-dose CFRT, both administered with neoadjuvant androgen suppression. Primary endpoints were biochemical-progression-free survival (bPFS), freedom from local progression, metastases-free survival, overall survival, and late toxicity scores. The toxicity scores were measured with questionnaires for physicians and patients that included the Radiation Therapy Oncology Group (RTOG), the Late Effects on Normal Tissue: Subjective/Objective/Management (LENT/SOM) scales, and the University of California, Los Angeles Prostate Cancer Index (UCLA PCI) scales. Analysis was done by intention to treat. This trial is registered at the Current Controlled Trials website http://www.controlled-trials.com/ISRCTN47772397. Findings Between January, 1998, and December, 2002, 843 men were randomly assigned to escalated-dose CFRT (n=422) or standard-dose CFRT (n=421). In the escalated group, the hazard ratio (HR) for bPFS was 0·67 (95% CI 0·53–0·85, p=0·0007). We noted 71% bPFS (108 cumulative events) and 60% bPFS (149 cumulative events) by 5 years in the escalated and standard groups, respectively. HR for clinical progression-free survival was 0·69 (0·47–1·02; p=0·064); local control was 0·65 (0·36–1·18; p=0·16); freedom from salvage androgen suppression was 0·78 (0·57–1·07; p=0·12); and metastases-free survival was 0·74 (0·47–1·18; p=0·21). HR for late bowel toxicity in the escalated group was 1·47 (1·12–1·92) according to the RTOG (grade ≥2) scale; 1·44 (1·16–1·80) according to the LENT/SOM (grade ≥2) scales; and 1·28 (1·03–1·60) according to the UCLA PCI (score ≥30) scale. 33% of the escalated and 24% of the standard group reported late bowel toxicity within 5 years of starting treatment. HR for late bladder toxicity according to the RTOG (grade ≥2) scale was 1·36 (0·90–2·06), but this finding was not supported by the LENT/SOM (grade ≥2) scales (HR 1·07 [0·90–1·29]), nor the UCLA PCI (score ≥30) scale (HR 1·05 [0·81–1·36]). Interpretation Escalated-dose CFRT with neoadjuvant androgen suppression seems clinically worthwhile in terms of bPFS, progression-free survival, and decreased use of salvage androgen suppression. This additional efficacy is offset by an increased incidence of longer term adverse events.</description><identifier>ISSN: 1470-2045</identifier><identifier>EISSN: 1474-5488</identifier><identifier>DOI: 10.1016/S1470-2045(07)70143-2</identifier><identifier>PMID: 17482880</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Aged ; Androgen Antagonists - therapeutic use ; Androgens ; Cancer therapies ; Disease control ; Disease-Free Survival ; Hematology, Oncology and Palliative Medicine ; Humans ; Male ; Metastasis ; Middle Aged ; Neoadjuvant Therapy ; Prostate cancer ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - radiotherapy ; Questionnaires ; Radiation therapy ; Radiotherapy Dosage ; Radiotherapy, Conformal ; Toxicity</subject><ispartof>The lancet oncology, 2007-06, Vol.8 (6), p.475-487</ispartof><rights>Elsevier Ltd</rights><rights>2007 Elsevier Ltd</rights><rights>Copyright Elsevier Limited Jun 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c445t-681b316880b1b33813e3453a22f8d43b52eb1a4b4d2d157f9a94d997896281673</citedby><cites>FETCH-LOGICAL-c445t-681b316880b1b33813e3453a22f8d43b52eb1a4b4d2d157f9a94d997896281673</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17482880$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dearnaley, David P, Dr</creatorcontrib><creatorcontrib>Sydes, Matthew R, CStat</creatorcontrib><creatorcontrib>Graham, John D, FRCR</creatorcontrib><creatorcontrib>Aird, Edwin G, PhD</creatorcontrib><creatorcontrib>Bottomley, David, FRCR</creatorcontrib><creatorcontrib>Cowan, Richard A, FRCR</creatorcontrib><creatorcontrib>Huddart, Robert A, FRCR</creatorcontrib><creatorcontrib>Jose, Chakiath C, FRACR</creatorcontrib><creatorcontrib>Matthews, John HL, FRACR</creatorcontrib><creatorcontrib>Millar, Jeremy, FRACR</creatorcontrib><creatorcontrib>Moore, A Rollo, MSc</creatorcontrib><creatorcontrib>Morgan, Rachel C, MSc</creatorcontrib><creatorcontrib>Russell, J Martin, FRCR</creatorcontrib><creatorcontrib>Scrase, Christopher D, FRCR</creatorcontrib><creatorcontrib>Stephens, Richard J</creatorcontrib><creatorcontrib>Syndikus, Isabel, FRCR</creatorcontrib><creatorcontrib>Parmar, Mahesh KB, DPhil</creatorcontrib><creatorcontrib>on behalf of the RT01 collaborators</creatorcontrib><creatorcontrib>RT01 collaborators</creatorcontrib><title>Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial</title><title>The lancet oncology</title><addtitle>Lancet Oncol</addtitle><description>Summary Background In men with localised prostate cancer, conformal radiotherapy (CFRT) could deliver higher doses of radiation than does standard-dose conventional radical external-beam radiotherapy, and could improve long-term efficacy, potentially at the cost of increased toxicity. We aimed to present the first analyses of effectiveness from the MRC RT01 randomised controlled trial. Methods The MRC RT01 trial included 843 men with localised prostate cancer who were randomly assigned to standard-dose CFRT or escalated-dose CFRT, both administered with neoadjuvant androgen suppression. Primary endpoints were biochemical-progression-free survival (bPFS), freedom from local progression, metastases-free survival, overall survival, and late toxicity scores. The toxicity scores were measured with questionnaires for physicians and patients that included the Radiation Therapy Oncology Group (RTOG), the Late Effects on Normal Tissue: Subjective/Objective/Management (LENT/SOM) scales, and the University of California, Los Angeles Prostate Cancer Index (UCLA PCI) scales. Analysis was done by intention to treat. This trial is registered at the Current Controlled Trials website http://www.controlled-trials.com/ISRCTN47772397. Findings Between January, 1998, and December, 2002, 843 men were randomly assigned to escalated-dose CFRT (n=422) or standard-dose CFRT (n=421). In the escalated group, the hazard ratio (HR) for bPFS was 0·67 (95% CI 0·53–0·85, p=0·0007). We noted 71% bPFS (108 cumulative events) and 60% bPFS (149 cumulative events) by 5 years in the escalated and standard groups, respectively. HR for clinical progression-free survival was 0·69 (0·47–1·02; p=0·064); local control was 0·65 (0·36–1·18; p=0·16); freedom from salvage androgen suppression was 0·78 (0·57–1·07; p=0·12); and metastases-free survival was 0·74 (0·47–1·18; p=0·21). HR for late bowel toxicity in the escalated group was 1·47 (1·12–1·92) according to the RTOG (grade ≥2) scale; 1·44 (1·16–1·80) according to the LENT/SOM (grade ≥2) scales; and 1·28 (1·03–1·60) according to the UCLA PCI (score ≥30) scale. 33% of the escalated and 24% of the standard group reported late bowel toxicity within 5 years of starting treatment. HR for late bladder toxicity according to the RTOG (grade ≥2) scale was 1·36 (0·90–2·06), but this finding was not supported by the LENT/SOM (grade ≥2) scales (HR 1·07 [0·90–1·29]), nor the UCLA PCI (score ≥30) scale (HR 1·05 [0·81–1·36]). Interpretation Escalated-dose CFRT with neoadjuvant androgen suppression seems clinically worthwhile in terms of bPFS, progression-free survival, and decreased use of salvage androgen suppression. This additional efficacy is offset by an increased incidence of longer term adverse events.</description><subject>Aged</subject><subject>Androgen Antagonists - therapeutic use</subject><subject>Androgens</subject><subject>Cancer therapies</subject><subject>Disease control</subject><subject>Disease-Free Survival</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Male</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Neoadjuvant Therapy</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - radiotherapy</subject><subject>Questionnaires</subject><subject>Radiation therapy</subject><subject>Radiotherapy Dosage</subject><subject>Radiotherapy, Conformal</subject><subject>Toxicity</subject><issn>1470-2045</issn><issn>1474-5488</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNqFkctu1TAQhi0EoqXwCCCLFV0EfEvssACho3KRipBKWVtOPBEuSXxqO5XOK_SpmXNyBBIb5IVHo2_-ufyEPOfsNWe8efOdK80qwVT9iulzzbiSlXhATjGtqloZ8_AQr8gJeZLzDWNcc1Y_JidcKyOMYafk_iL3bnQFfOVjBnoHKS-Z5uJm79Ix2cd5iGlyI03Oh1h-QnLbHQ0z3aaIaEHEzT2kt3QIKReaIC9jyXRIcaKI069XG3p1zTgKzD5OIYPfq5YUxxHDkoIbn5JHgxszPDv-Z-THx4vrzefq8tunL5sPl1WvVF2qxvBO8gan7zCQhkuQqpZOiMF4JbtaQMed6pQXntd6aF2rfNtq0zbC8EbLM_Jy1cXhbxfIxd7EJc3Y0grGEMSHUL1CPW6YEwx2m8Lk0s5yZvcG2IMBdn9dy7Q9GGAF1r04ii_dBP5v1fHiCLxfAcAV7wIkm_sAeDwfEvTF-hj-2-LdPwr9GOaANv6CHeQ_y3CbhWWryF6D6YOCkL8BtmuqkQ</recordid><startdate>20070601</startdate><enddate>20070601</enddate><creator>Dearnaley, David P, Dr</creator><creator>Sydes, Matthew R, CStat</creator><creator>Graham, John D, FRCR</creator><creator>Aird, Edwin G, PhD</creator><creator>Bottomley, David, FRCR</creator><creator>Cowan, Richard A, FRCR</creator><creator>Huddart, Robert A, FRCR</creator><creator>Jose, Chakiath C, FRACR</creator><creator>Matthews, John HL, FRACR</creator><creator>Millar, Jeremy, FRACR</creator><creator>Moore, A Rollo, MSc</creator><creator>Morgan, Rachel C, MSc</creator><creator>Russell, J Martin, FRCR</creator><creator>Scrase, Christopher D, FRCR</creator><creator>Stephens, Richard J</creator><creator>Syndikus, Isabel, FRCR</creator><creator>Parmar, Mahesh KB, DPhil</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20070601</creationdate><title>Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial</title><author>Dearnaley, David P, Dr ; Sydes, Matthew R, CStat ; Graham, John D, FRCR ; Aird, Edwin G, PhD ; Bottomley, David, FRCR ; Cowan, Richard A, FRCR ; Huddart, Robert A, FRCR ; Jose, Chakiath C, FRACR ; Matthews, John HL, FRACR ; Millar, Jeremy, FRACR ; Moore, A Rollo, MSc ; Morgan, Rachel C, MSc ; Russell, J Martin, FRCR ; Scrase, Christopher D, FRCR ; Stephens, Richard J ; Syndikus, Isabel, FRCR ; Parmar, Mahesh KB, DPhil</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c445t-681b316880b1b33813e3453a22f8d43b52eb1a4b4d2d157f9a94d997896281673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Aged</topic><topic>Androgen Antagonists - therapeutic use</topic><topic>Androgens</topic><topic>Cancer therapies</topic><topic>Disease control</topic><topic>Disease-Free Survival</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Male</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Neoadjuvant Therapy</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - radiotherapy</topic><topic>Questionnaires</topic><topic>Radiation therapy</topic><topic>Radiotherapy Dosage</topic><topic>Radiotherapy, Conformal</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dearnaley, David P, Dr</creatorcontrib><creatorcontrib>Sydes, Matthew R, CStat</creatorcontrib><creatorcontrib>Graham, John D, FRCR</creatorcontrib><creatorcontrib>Aird, Edwin G, PhD</creatorcontrib><creatorcontrib>Bottomley, David, FRCR</creatorcontrib><creatorcontrib>Cowan, Richard A, FRCR</creatorcontrib><creatorcontrib>Huddart, Robert A, FRCR</creatorcontrib><creatorcontrib>Jose, Chakiath C, FRACR</creatorcontrib><creatorcontrib>Matthews, John HL, FRACR</creatorcontrib><creatorcontrib>Millar, Jeremy, FRACR</creatorcontrib><creatorcontrib>Moore, A Rollo, MSc</creatorcontrib><creatorcontrib>Morgan, Rachel C, MSc</creatorcontrib><creatorcontrib>Russell, J Martin, FRCR</creatorcontrib><creatorcontrib>Scrase, Christopher D, FRCR</creatorcontrib><creatorcontrib>Stephens, Richard J</creatorcontrib><creatorcontrib>Syndikus, Isabel, FRCR</creatorcontrib><creatorcontrib>Parmar, Mahesh KB, DPhil</creatorcontrib><creatorcontrib>on behalf of the RT01 collaborators</creatorcontrib><creatorcontrib>RT01 collaborators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Complete (ProQuest Database)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>The lancet oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dearnaley, David P, Dr</au><au>Sydes, Matthew R, CStat</au><au>Graham, John D, FRCR</au><au>Aird, Edwin G, PhD</au><au>Bottomley, David, FRCR</au><au>Cowan, Richard A, FRCR</au><au>Huddart, Robert A, FRCR</au><au>Jose, Chakiath C, FRACR</au><au>Matthews, John HL, FRACR</au><au>Millar, Jeremy, FRACR</au><au>Moore, A Rollo, MSc</au><au>Morgan, Rachel C, MSc</au><au>Russell, J Martin, FRCR</au><au>Scrase, Christopher D, FRCR</au><au>Stephens, Richard J</au><au>Syndikus, Isabel, FRCR</au><au>Parmar, Mahesh KB, DPhil</au><aucorp>on behalf of the RT01 collaborators</aucorp><aucorp>RT01 collaborators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial</atitle><jtitle>The lancet oncology</jtitle><addtitle>Lancet Oncol</addtitle><date>2007-06-01</date><risdate>2007</risdate><volume>8</volume><issue>6</issue><spage>475</spage><epage>487</epage><pages>475-487</pages><issn>1470-2045</issn><eissn>1474-5488</eissn><coden>LANCAO</coden><abstract>Summary Background In men with localised prostate cancer, conformal radiotherapy (CFRT) could deliver higher doses of radiation than does standard-dose conventional radical external-beam radiotherapy, and could improve long-term efficacy, potentially at the cost of increased toxicity. We aimed to present the first analyses of effectiveness from the MRC RT01 randomised controlled trial. Methods The MRC RT01 trial included 843 men with localised prostate cancer who were randomly assigned to standard-dose CFRT or escalated-dose CFRT, both administered with neoadjuvant androgen suppression. Primary endpoints were biochemical-progression-free survival (bPFS), freedom from local progression, metastases-free survival, overall survival, and late toxicity scores. The toxicity scores were measured with questionnaires for physicians and patients that included the Radiation Therapy Oncology Group (RTOG), the Late Effects on Normal Tissue: Subjective/Objective/Management (LENT/SOM) scales, and the University of California, Los Angeles Prostate Cancer Index (UCLA PCI) scales. Analysis was done by intention to treat. This trial is registered at the Current Controlled Trials website http://www.controlled-trials.com/ISRCTN47772397. Findings Between January, 1998, and December, 2002, 843 men were randomly assigned to escalated-dose CFRT (n=422) or standard-dose CFRT (n=421). In the escalated group, the hazard ratio (HR) for bPFS was 0·67 (95% CI 0·53–0·85, p=0·0007). We noted 71% bPFS (108 cumulative events) and 60% bPFS (149 cumulative events) by 5 years in the escalated and standard groups, respectively. HR for clinical progression-free survival was 0·69 (0·47–1·02; p=0·064); local control was 0·65 (0·36–1·18; p=0·16); freedom from salvage androgen suppression was 0·78 (0·57–1·07; p=0·12); and metastases-free survival was 0·74 (0·47–1·18; p=0·21). HR for late bowel toxicity in the escalated group was 1·47 (1·12–1·92) according to the RTOG (grade ≥2) scale; 1·44 (1·16–1·80) according to the LENT/SOM (grade ≥2) scales; and 1·28 (1·03–1·60) according to the UCLA PCI (score ≥30) scale. 33% of the escalated and 24% of the standard group reported late bowel toxicity within 5 years of starting treatment. HR for late bladder toxicity according to the RTOG (grade ≥2) scale was 1·36 (0·90–2·06), but this finding was not supported by the LENT/SOM (grade ≥2) scales (HR 1·07 [0·90–1·29]), nor the UCLA PCI (score ≥30) scale (HR 1·05 [0·81–1·36]). Interpretation Escalated-dose CFRT with neoadjuvant androgen suppression seems clinically worthwhile in terms of bPFS, progression-free survival, and decreased use of salvage androgen suppression. This additional efficacy is offset by an increased incidence of longer term adverse events.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>17482880</pmid><doi>10.1016/S1470-2045(07)70143-2</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1470-2045
ispartof The lancet oncology, 2007-06, Vol.8 (6), p.475-487
issn 1470-2045
1474-5488
language eng
recordid cdi_proquest_journals_200978787
source ScienceDirect Freedom Collection
subjects Aged
Androgen Antagonists - therapeutic use
Androgens
Cancer therapies
Disease control
Disease-Free Survival
Hematology, Oncology and Palliative Medicine
Humans
Male
Metastasis
Middle Aged
Neoadjuvant Therapy
Prostate cancer
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - radiotherapy
Questionnaires
Radiation therapy
Radiotherapy Dosage
Radiotherapy, Conformal
Toxicity
title Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T19%3A18%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Escalated-dose%20versus%20standard-dose%20conformal%20radiotherapy%20in%20prostate%20cancer:%20first%20results%20from%20the%20MRC%20RT01%20randomised%20controlled%20trial&rft.jtitle=The%20lancet%20oncology&rft.au=Dearnaley,%20David%20P,%20Dr&rft.aucorp=on%20behalf%20of%20the%20RT01%20collaborators&rft.date=2007-06-01&rft.volume=8&rft.issue=6&rft.spage=475&rft.epage=487&rft.pages=475-487&rft.issn=1470-2045&rft.eissn=1474-5488&rft.coden=LANCAO&rft_id=info:doi/10.1016/S1470-2045(07)70143-2&rft_dat=%3Cproquest_cross%3E1665199821%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c445t-681b316880b1b33813e3453a22f8d43b52eb1a4b4d2d157f9a94d997896281673%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=200978787&rft_id=info:pmid/17482880&rfr_iscdi=true